EFFECT OF VALSARTAN AND OLMESARTAN ON POLYMORPHISM OF NO-SYNTHASE GENES
DOI:
https://doi.org/10.11603/1811-2471.2024.v.i4.15026Keywords:
arterial hypertension, nitric oxide synthase, gene polymorphism, personalized medicine, antihypertensive drugsAbstract
SUMMARY. The aim – to analyze current data on the impact of valsartan and olmesartan on nitric oxide synthase gene polymorphisms and its consequences for the effectiveness of arterial hypertension treatment.
Material and Methods. The study material comprised data from the literature of the past 5-10 years related to arterial hypertension, nitric oxide synthase, gene polymorphism, and the effects of antihypertensive drugs.
Results. While valsartan and olmesartan do not directly affect nitric oxide synthase activity, they indirectly increase nitric oxide production. The effectiveness of these drugs depends on the individual genetic characteristics of the patient, particularly on nitric oxide synthase gene polymorphisms. It has been shown that a genetic test can help select the optimal dose and combination of drugs for each patient with arterial hypertension. This allows for increased treatment efficacy and reduced risk of adverse side effects. However, further research and the development of standard protocols are necessary for the widespread use of genetic tests in clinical practice. Thus, understanding the interaction between drugs and genetic factors opens new perspectives for personalized therapy of arterial hypertension.
Conclusions: Valsartan and olmesartan indirectly stimulate NO production. Nitric oxide synthase gene polymorphism affects the effectiveness of these drugs. A genetic test allows for individualized therapy for patients with arterial hypertension, increasing its efficacy and reducing the risk of side effects. However, additional research is needed for the widespread use of genetic tests.
Key Points:
- Valsartan and olmesartan affect NO through angiotensin II receptors.
- Nitric oxide synthase gene polymorphism affects the body’s response to these drugs.
- A genetic test helps select the optimal treatment for each patient.
- Further research is necessary for the wider use of genetic tests in clinical practice.
This approach allows for the personalization of arterial hypertension treatment and improves the prognosis for patients.
References
Tseluyko, V. I. (2019). Prognostic value of systolic blood pressure increase and its correction in Ukrainian patients with arterial hypertension: the results of cohort study Systema-2. Ukrainian Journal of Cardiology, 26(3), 9-16. DOI: 10.31928/1608-635x-2019.3.916 DOI: https://doi.org/10.31928/1608-635X-2019.3.916
Ivanochko, R., Abrahamovych, O., & Kravchuk, I. (2020). Features of the Functional State of the L-arginine / NO-synthase / Arginase System and Oxidative Processes in Patients with end-stage Renal Disease due to Chronic Glomerulonephritis Before and After a Hemodialysis Session. Lviv clinical bulletin, 3(31), 37-45. DOI: 10.25040/lkv2020. 03.037 DOI: https://doi.org/10.25040/lkv2020.03.037
Chan, S. H. H., & Chan, J. Y. H. (2014). Brain Stem NOS and ROS in Neural Mechanisms of Hypertension. Antioxidants & Redox Signaling, 20(1), 146-163. DOI: 10.1089/ars.2013.5230 DOI: https://doi.org/10.1089/ars.2013.5230
Tseluyko, V. I., & Yarova, O. D. (2018). Echocardiography indicators in patients with atherosclerosis of peripheral arteries of the lower extremities dependent on T(–786)C polymorphism of the endothelial nitric oxide synthase gene promoter. Cardiac Surgery and Interventional Cardiology, (1), 25-31. DOI: 10.31928/2305-3127-2018.1.2531 DOI: https://doi.org/10.31928/2305-3127-2018.1.2531
Kotiuzhynska, S. H., & Umanskyy, D. O. (2019). Aterosclerosis and inflammation: general pathogenetic mechanisms. Precarpathian bulletin of the Shevchenko scientific society Pulse, 6(58), 31-37. DOI: 10.21802/2304-7437-2019-6(58)-31-37 DOI: https://doi.org/10.21802/10.21802/2304-7437-2019-6(58)-31-37
Ovcharenko, L. K., Tsіganenko, I. V., & Zaіats, Y. B. (2022). Chronic heart failure: cause or result? Actual Problems of the Modern Medicine: Bulletin of Ukrainian Medical Stomatological Academy, 22(1), 196-202. DOI: 10.31718/ 2077-1096.22.1.196 DOI: https://doi.org/10.31718/2077-1096.22.1.196
Bereziuk, О. V., Gorbatiuk, S. М., Klymchuk, І. M., & Shevchuk, Т. І. (2021). Dependence of the celebral apoplexy mobidity rate of the productive age population on the performance of the waste incineration plant. Scientific Works of Vinnytsia National Technical University, (4). DOI: 10.31649/2307-5376-2021-4-7-12 DOI: https://doi.org/10.31649/2307-5376-2021-4-7-12
Gehani, A. A., Al-Hinai, A. T., Zubaid, M., Almahmeed, W., Hasani, M. R. M., Yusufali, A. H., … Yusuf, S. (2012). Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. European Journal of Preventive Cardiology, 21(4), 400-410. DOI: 10.1177/2047487312465525 DOI: https://doi.org/10.1177/2047487312465525
Kravchuk, Zh. M., Artysh, B. I., Kubeš, V., Sotnychenko, N. M., & Doroshenko, A. M. (2019). Bioekvivalentnist henerychnoho likarskoho zasobu fiksovanoi kombinatsii amlodypinu, hidrokhlorotiazydu i valsartanu (Tiara Trio®) referentnomu likarskomu zasobu Exforge NST®: rezultaty randomizovanoho perekhresnoho klinichnoho doslidzhennia u zdorovykh dobrovoltsiv [Bioequivalence of amlodipine, hydrochlorothiazide and valsartan fixed-dose combination generic medicinal product (Tiara Trio®) to the reference medicinal product Exforge HCT®: results of a randomized crossover clinical trial in healthy volunteers]. Ukrayin'skyy medychnyy zhurnal - Ukrainian Medical Journal. DOI: 10.32471/umj.1680-3051.132.162000 [in Ukrainian] DOI: https://doi.org/10.32471/umj.1680-3051.132.162000
Sklyarov, Е. YA., & Bochar, O. M. (2016). Riven interleikinu-6 u patsiientiv z esentsiinoiu hipertenziieiu u poiednanni z ozhyrinniam pry pryznachenni telmisartanu abo olmesartanu v kompleksnii terapii z atorvastatynom [Level of interleukin-6 in patients with essential hypertension combined with obesity at administration of olmesartan or telmisartan in complex therapy with atorvastatin]. Bukovyns'kyy medychnyy visnyk - Bukovinian Medical Herald, 2(78), 162-165. DOI: 10.24061/2413-0737.xx.2.78.2016.98 [in Ukrainian] DOI: https://doi.org/10.24061/2413-0737.XX.2.78.2016.98
Shorikov, E.I. (2016). Vprovadzhennia donatoriv oksydu azotu v umovakh hipertonichnoi khvoroby za poiednanoho perebihu z tsukrovym diabetom 2-ho typu z urakhuvanniam ahrehatsiinykh vlastyvostei trombotsytiv [Application of nitric oxide donors in patients with hypertension combined with diabetes mellitus type 2 by assessing parameters of the platelet aggregation]. Bukovyns'kyy medychnyy visnyk - Bukovinian Medical Herald, 1(77), 184-187. DOI: 10.24061/2413-0737.xx.1.77.2016.41 [in Ukrainian] DOI: https://doi.org/10.24061/2413-0737.XX.1.77.2016.41
Tseluyko, V. Y., Yakovleva, L. M., & Luchkov, A. B. (2013). Pokaznyky vnutrishnosertsevoi hemodynamiky u khvorykh na ishemichnu khvorobu sertsia zalezhno vid polimorfizmu T-786C promotoru hena endotelialnoi NO-syntazy [Intracardiac Hemodynamics Indicators in Patients with Coronary Artery Disease Depending on T-786C Polymorphism of Endothelial NO-Synthase Gene Promoter]. Medytsyna Nevidkladnykh Staniv - Emergency medicine, 8(55), 99-104. DOI: 10.22141/2224-0586.8.55.2013.88576 [in Ukrainian] DOI: https://doi.org/10.22141/2224-0586.8.55.2013.88576
